← Leaderboards
Farhad Parhami
University Of California Los Angeles
$7,690,399
Attributed
$7,690,399
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,690,399 · 8
By mechanism
R44$3,494,231 · 2
R01$3,333,659 · 2
R43$862,509 · 3
P60$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Edward M De Robertis$3,809,117
- Jay R. Lieberman$6,899,796
- James I Kim$539,752
- Linda M Liau$8,990,878
- Kang Ting$4,639,388
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroLiverSignal TransductionResponsePathway InteractionsFamilyReportingMolecularPropertyStructure-Activity RelationshipCellsCollagenMediatingLipid BiosynthesisOsteogenesisInvestigationBone Morphogenetic ProteinsErinaceidaeBone MarrowAnalogMorbidity - Disease RateSignal PathwayLigands
Grant awards (19)
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis$889,701
R44 · FY2024 · DK · contact PI
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis$896,990
R44 · FY2023 · DK · contact PI
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion$852,387
R44 · FY2022 · AR · contact PI
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH$320,724
R43 · FY2022 · HL · contact PI
An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling$318,089
R43 · FY2022 · HL · contact PI
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion$855,153
R44 · FY2021 · AR · contact PI
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH$223,696
R43 · FY2020 · DK · contact PI
Development of Osteogenic Oxysterols for Local Bone Formation$346,500
R01 · FY2015 · AR · contact PI
Development of Osteogenic Oxysterols for Local Bone Formation$339,570
R01 · FY2014 · AR · contact PI
Development of Osteogenic Oxysterols for Local Bone Formation$329,175
R01 · FY2013 · AR · contact PI
Development of Osteogenic Oxysterols for Local Bone Formation$346,500
R01 · FY2012 · AR · contact PI
Development of Osteogenic Oxysterols for Local Bone Formation$346,500
R01 · FY2011 · AR · contact PI
Oxysterols Regulate Marrow Stromal Cell Differentiation$315,841
R01 · FY2009 · AR · contact PI
Oxysterols Regulate Marrow Stromal Cell Differentiation$315,841
R01 · FY2008 · AR · contact PI
Oxysterols Regulate Marrow Stromal Cell Differentiation$322,287
R01 · FY2007 · AR · contact PI
Oxysterois Regulate Marrow Stromal Cell Differentiation$331,912
R01 · FY2006 · AR · contact PI
Oxysterols Regulate Marrow Stromal Cell Differentiation$339,533
R01 · FY2005 · AR
EFFECTS OF LIPID OXIDATION PRODUCTS ON BONE METABOLISM$0
P60 · FY2002 · AG
EFFECTS OF LIPID OXIDATION PRODUCTS ON BONE METABOLISM$0
P60 · FY2001 · AG